Bruker (NASDAQ:BRKR) Given a $40.00 Price Target by Stifel Nicolaus Analysts

Key Points

• Stifel Nicolaus has lowered its price target for Bruker (NASDAQ:BRKR) from $48.00 to $40.00, maintaining a "hold" rating, suggesting a potential upside of 15.21% from the prior close.
• Bruker reported quarterly earnings of $0.32 per share, which was below analysts' expectations of $0.43, contributing to a revenue decline of 0.4% compared to the same quarter last year.
• In recent trading, Bruker shares opened at $34.72, with a market capitalization of $5.26 billion and a current average price target of $52.30 from analysts, indicating a generally cautious sentiment surrounding the stock.

Bruker (NASDAQ:BRKR - Get Free Report) has been given a $40.00 target price by equities research analysts at Stifel Nicolaus in a research note issued to investors on Tuesday, Marketbeat Ratings reports. The firm currently has a "hold" rating on the medical research company's stock. Stifel Nicolaus' target price points to a potential upside of 24.73% from the stock's previous close.

BRKR has been the subject of a number of other research reports. Bank of America cut their price target on shares of Bruker from $61.00 to $50.00 and set a "buy" rating for the company in a report on Thursday, June 26th. Jefferies Financial Group lowered their price objective on shares of Bruker from $70.00 to $60.00 and set a "buy" rating on the stock in a research note on Monday. The Goldman Sachs Group lowered their price objective on shares of Bruker from $50.00 to $45.00 and set a "neutral" rating on the stock in a research note on Thursday, May 8th. Citigroup lowered their price objective on shares of Bruker from $40.00 to $38.00 and set a "neutral" rating on the stock in a research note on Monday. Finally, Wells Fargo & Company lowered their price objective on shares of Bruker from $75.00 to $60.00 and set an "overweight" rating on the stock in a research note on Thursday, April 17th. Six analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $51.30.

Bruker Stock Down 7.6%

Shares of Bruker stock opened at $32.07 on Tuesday. The company has a market cap of $4.86 billion, a P/E ratio of 61.67, a PEG ratio of 2.34 and a beta of 1.16. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.74 and a current ratio of 1.61. Bruker has a one year low of $32.01 and a one year high of $72.94. The firm has a fifty day moving average of $39.83 and a two-hundred day moving average of $43.12.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The medical research company reported $0.32 EPS for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The firm had revenue of $797.40 million for the quarter, compared to analysts' expectations of $811.17 million. Bruker had a return on equity of 17.89% and a net margin of 2.31%. The firm's quarterly revenue was down .4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS. On average, analysts forecast that Bruker will post 2.69 earnings per share for the current year.

Insider Activity

In other news, CEO Frank H. Laukien acquired 2,608 shares of the company's stock in a transaction dated Friday, June 6th. The shares were bought at an average price of $38.36 per share, for a total transaction of $100,042.88. Following the completion of the purchase, the chief executive officer directly owned 38,462,171 shares of the company's stock, valued at approximately $1,475,408,879.56. This trade represents a 0.01% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 27.30% of the stock is owned by corporate insiders.

Institutional Trading of Bruker

Hedge funds have recently made changes to their positions in the company. Teacher Retirement System of Texas grew its position in shares of Bruker by 5.1% during the first quarter. Teacher Retirement System of Texas now owns 29,045 shares of the medical research company's stock worth $1,212,000 after buying an additional 1,422 shares in the last quarter. Fifth Third Bancorp boosted its holdings in shares of Bruker by 54.2% during the first quarter. Fifth Third Bancorp now owns 1,109 shares of the medical research company's stock valued at $46,000 after acquiring an additional 390 shares during the period. Wealth Enhancement Advisory Services LLC grew its position in shares of Bruker by 81.2% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 29,826 shares of the medical research company's stock worth $1,245,000 after acquiring an additional 13,367 shares during the last quarter. OneDigital Investment Advisors LLC grew its position in shares of Bruker by 38.0% during the first quarter. OneDigital Investment Advisors LLC now owns 5,522 shares of the medical research company's stock worth $230,000 after acquiring an additional 1,520 shares during the last quarter. Finally, Sterling Capital Management LLC grew its position in shares of Bruker by 29.0% during the fourth quarter. Sterling Capital Management LLC now owns 3,514 shares of the medical research company's stock worth $206,000 after acquiring an additional 791 shares during the last quarter. Hedge funds and other institutional investors own 79.52% of the company's stock.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.